MalawiTuberculosis profile
Population  2014 17 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.8 (1.6–4.4) 17 (9.7–26)
Mortality (HIV+TB only) 7 (4.1–11) 42 (25–64)
Prevalence  (includes HIV+TB) 56 (26–97) 334 (156–578)
Incidence  (includes HIV+TB) 38 (20–61) 227 (122–365)
Incidence (HIV+TB only) 19 (10–31) 115 (60–186)
         
Case detection, all forms (%) 43 (27–80)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.42 (0.14–0.97) 4.8 (3.2–6.9)
MDR-TB cases among notified pulmonary
TB cases
47 (16–110) 97 (65–140)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 564   547
Pulmonary, clinically diagnosed 5 589   0
Extrapulmonary 4 567   0
       
Total new and relapse 16 267    
Previously treated, excluding relapses 1 456    
Total cases notified 17 723    
Among 16 267 new and relapse cases:
1 827 (11%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 40 (<1%) 615 (31%) 14 172
Laboratory-confirmed RR-/MDR-TB cases     106
Patients started on MDR-TB treatment ***     64
TB/HIV 2014 Number (%)
TB patients with known HIV status 16 445 (93)
HIV-positive TB patients 8 844 (54)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 995 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 8 162 (92)
HIV-positive people screened for TB 515 554  
HIV-positive people provided with IPT 135 013  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (82) 17 779
Previously treated cases, excluding relapse, registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (63) 19
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 0.6
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 42
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 19
% Funded domestically 11%
% Funded internationally 89%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-01 Data: www.who.int/tb/data